|
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection Clinical research trials and Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection. Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection clinical trial. Participants typically obtain the most effective healthcare available for their Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection  Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection
For Condition: Acquired Immunodeficiency Syndrome,Mycobacterium avium-intracellulare Infection
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: Disseminated infection with Mycobacteria avium complex (MAC) is one of the most common systemic bacterial infections in advanced stages of the acquired immunodeficiency syndrome (AIDS). Current therapy for disseminated MAC infection in HIV patients consists of multidrug chemotherapy regimens are often accompanied by toxicities, and many patients become intolerant of one or more agents. Macrolides are the essential component of successful therapy, yet macrolide resistant strains are being recognized with increasing frequency. Thus, there is an interest in identifying additional therapeutic interventions for disseminated MAC in HIV-infected patients. Interleukin-12 (IL-12) is a central, regulatory cytokine in cell-mediated immunity. IL-12 enhances the cytolytic activity of cytotoxic T and NK cells, and induces interferon-gamma (IFN gamma) production from T and NK cells. This open-label Phase I study is designed to evaluate the safety and immunologic/microbiologic effects of interleukin-12 administration in HIV-infected patients with concomitant disseminated Mycobacterium avium (MAC) infection. Fifteen patients with documented disseminated MAC will be randomized to receive double-blinded placebo or escalating doses of IL-12 in addition to anti-MAC chemotherapy and standard anti-retroviral therapy for six weeks. IL-12 will be administered subcutaneously, with escalating doses every month over the dose range of 30 ng/kg, 100 ng/kg, and 300 ng/kg, or until an individual maximum tolerated dose (IMTD) is reached. Should a patient receive 2 consecutive blood cultures negative for MAC during the course of the study at a lower dose, then he/she will not be further dose escalated. Those patients receiving placebo after 6 weeks will be crossed over to receive the full treatment course of IL-12. Each new dose or dose escalation will take place on an inpatient basis. Once a patient is clinically stable at a dose, the patient will be maintained at that dose as an outpatient for the remainder of the month. Total IL-12 administration will not exceed 12 weeks, or 24 total doses.
Details: Disseminated infection with Mycobacteria avium complex (MAC) is one of the most common systemic bacterial infections in advanced stages of the acquired immunodeficiency syndrome (AIDS). Current therapy for disseminated MAC infection in HIV patients consists of multidrug chemotherapy regimens are often accompanied by toxicities, and many patients become intolerant of one or more agents. Macrolides are the essential component of successful therapy, yet macrolide resistant strains are being recognized with increasing frequency. Thus, there is an interest in identifying additional therapeutic interventions for disseminated MAC in HIV-infected patients. Interleukin-12 (IL-12) is a central, regulatory cytokine in cell-mediated immunity. IL-12 enhances the cytolytic activity of cytotoxic T and NK cells, and induces interferon-gamma (IFN gamma) production from T and NK cells. This open-label Phase I study is designed to evaluate the safety and immunologic/microbiologic effects of interleukin-12 administration in HIV-infected patients with concomitant disseminated Mycobacterium avium (MAC) infection or localized MAC infection. Fifteen patients with documented disseminated MAC will be randomized to receive double-blinded placebo or escalating doses of IL-12 in addition to anti-MAC chemotherapy and standard anti-retroviral therapy for six weeks. IL-12 will be administered subcutaneously, with escalating doses every month over the dose range of 30 ng/kg, 100 ng/kg, and 300 ng/kg, or until an individual maximum tolerated dose (IMTD) is reached. Should a patient receive 2 consecutive blood cultures negative for MAC during the course of the study at a lower dose, then he/she will not be further dose escalated. Likewise, patients with localized disease will not be further dose escalated if symptoms/evidence of localized infection resolve as assessed by the principal investigator. Those patients receiving placebo after 6 weeks will be crossed over to receive the full treatment course of IL-12. Each new dose or dose escalation will take place on an inpatient basis. Once a patient is clinically stable at a dose, the patient will be maintained at that dose as an outpatient for the remainder of the month. Total IL-12 administration will not exceed 12 weeks, or 24 total doses.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Documented HIV infection (ELISA and Western blot positive). 18 years or older. Clinically stable enough to travel to NIH and meet protocol schedule requirements. Negative urine or serum pregnancy test within 14 days prior to study entry (for women of childbearing potential). Patients should be receiving a combination of FDA approved antiretroviral drugs or expanded access antiretroviral therapy for at least two weeks prior to study entry. The exception would be that, in the opinion of the primary treating physician, this therapy would not likely provide benefit. Greater than or equal to 1 positive blood culture or 1 positive culture from a normally sterile site (e.g. lymph node, bone marrow, etc.) for MAC within 6 weeks of study. The initial screening blood culture at the NIH must be positive. The following lab values must be present at study entry: Transaminases, alkaline phosphatase, total bilirubin less than or equal to 5x upper limit of normal range. Serum creatinine less than or equal to 2.0 mg/ml. Proteinuria less than or equal to positive 1. Normal PT/PTT. Granulocyte count greater than or equal to 750/cubic millimeter. Hemoglobin greater than or equal to 8 gm/dL and platelet count greater than or equal to 75,000. Fasting Blood glucose 1.25x upper normal limit (126 g/dl). (In persons with no history of diabetes.) No malignancy other than Kaposi sarcoma. Patients with Kaposi sarcoma are eligible, but must not have received systemic therapy for KS. No current life threatening AIDS related opportunistic infection other than disseminated MAC. No evidence of active substance abuse according to the standard 8th floor clinic substance abuse assessment, which allows enrollment at the discretion of the principal investigator. No patients exhibiting psychiatric disturbance or illness, which in the assessment of the protocol team may affect patient safety or compliance. No significant cardiac, gastrointestinal, pulmonary, autoimmune, renal, or CNS disease which could interfere with patient safety. No hypertension requiring anti-hypertensive therapy. No pregnant or lactating patients, or any patient with an inability or unwillingness to use effective contraception. Willingness to comply with current NIH Clinical Center guidelines concerning appropriate notification by an individual of current or ongoing sexual partners and/or needle-sharing partners regarding his or her HIV seropositivity and the risk of transmission of HIV infection.
Total Enrollment: 15
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 980091; 98-I-0091
Study Start Date: April 24, 1998
Record last reviewed: April 23, 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001763
Other Mycobacterium Avium-Intracellulare Infection Studies:
1. The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children with AIDS
2. A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 mg) or Rifabutin (300 mg) or Placebo
3. Evaluation of the Therapeutic Benefit of r-metHuIFN- gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study
4. A Study of Viracept in AIDS Patients with Mycobacterium Avium Complex Disease (MAC)
5. A Study of Rifabutin, Used Alone or with Ethambutol in the Prevention of Mycobacterium avium Complex (MAC) Bacteremia in Patients with AIDS
Related Studies:
Other Mycobacterium avium-intracellulare Infection Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients with Disseminated Mycobacterium Avium Complex Infection
|
|
|
|
|
|
|
|
